lifesciences
Innopsys

InnoScan 710-IR

Documents Description Produits
The first "DNA arrays" technological application, developed successfully, was the "expression profiling". It is still today the most largely employed application and which is in full expansion since...
Lire la suite
Technical note Abstract This technical note is focused on the application of the InnoScan® 710 and 710IR scanners to scan protein arrays. Its principal goal is to guide customers and...
Lire la suite
Innopsys presented its infrared microarray scanner at the RPPA Global workshop in Virginia in October. The RPPA workshop allowed community to learn about new developments and challenges for RPPA. Dr....
Lire la suite
Protein microarrays are the template of choice for many diagnostic applications and proteomic analyses. Reverse Phase Protein Arrays (RPPA) enable the protein content analysis of hundreds of samples...
Lire la suite
Reverse Phase Protein Arrays (RPPAs) are increasingly used to study cell signaling as they are highly multiplexed and allow precise quantification of protein of interests in biological samples. Such...
Lire la suite
Reverse Phase Protein Arrays (RPPA) also named cell lysate arrays have been shown to be useful tools for biomarker evaluation in large patient cohorts. Using validated antibodies, biomarkers of cell...
Lire la suite
Cytokines are a class of proteins that have emerging roles in diagnostics and therapeutics due to their role in cell signaling and immune system response1,2. Many key cytokines including...
Lire la suite
Protein arrays are widely used to measure protein expression in biological samples. One of the principal challenges on protein array technologies is to keep protein activity intact while immobilising...
Lire la suite
Reverse Phase Protein Arrays (RPPAs) are a specific type of protein arrays consisting of printed cell lysates useful for cell signaling and biomarker analysis. RPPAs are mainly built on...
Lire la suite

SIÈGE SOCIAL

Parc d'activités Activestre
31390 Carbonne - FRANCE

CONTACT

Tél. +33 561 971 974
Fax +33 561 971 975